Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing
Eli Lilly has tapped another gene editing partner, this time looking to go after a large patient population in the cardiovascular space with the help of Verve Therapeutics.
As part of an in vivo gene editing deal, the Indianapolis Big Pharma will pay the Boston biotech $30 million in cash, invest $30 million via equity at a 15% premium to the 30-day volume-weighted average price, and contribute up to another $465 million in R&D and commercial milestones, Verve CEO and co-founder Sekar Kathiresan told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.